A systematic literature review of Janus kinase inhibitors for the treatment of systemic sclerosis.

ABSTRACT:

Objectives

The use of Janus kinase inhibitors is increasing in systemic sclerosis, a complex autoimmune disease characterized by fibrosis, vasculopathy, and immune dysregulation. In this review, we aimed to examine the studies in the literature reporting on patients with systemic sclerosis treated with Janus kinase inhibitors.

Methods

We performed a search on MEDLINE and Scopus for articles involving patients with systemic sclerosis treated with Janus kinase inhibitors from the inception of these databases through 1 August 2024.

Results

Our literature search revealed 18 articles describing 87 systemic sclerosis patients treated with Janus kinase inhibitors. The median (min-max) age of these patients was 48.5 (13-78) years (F/M = 4.9). The most commonly used Janus kina

SUBMITTER: Sener S 

PROVIDER: S-EPMC12102077 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature